S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
NASDAQ:EYPT

EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

$27.21
-0.47 (-1.70%)
(As of 02/29/2024 ET)
Today's Range
$27.08
$28.33
50-Day Range
$19.93
$29.71
52-Week Range
$2.21
$30.99
Volume
1.70 million shs
Average Volume
995,482 shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.86

EyePoint Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
24.4% Upside
$33.86 Price Target
Short Interest
Healthy
10.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of EyePoint Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$68.92 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.04) to ($1.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.04 out of 5 stars

Medical Sector

415th out of 957 stocks

Analytical Instruments Industry

13th out of 29 stocks


EYPT stock logo

About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT Stock Price History

EYPT Stock News Headlines

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.4% Higher
EYPT Jul 2024 30.000 put
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
EYPT May 2024 30.000 put
EyePoint Is Betting The Bank On EYP-1901
EYPT Mar 2024 25.000 put
EYPT Mar 2024 40.000 call
Insider Buying at These Biotechs Is Huge
See More Headlines
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
3/01/2024
Next Earnings (Estimated)
3/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:EYPT
Employees
144
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$33.86
High Stock Price Target
$44.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+24.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-102,250,000.00
Net Margins
-235.51%
Pretax Margin
-235.51%

Debt

Sales & Book Value

Annual Sales
$41.40 million
Book Value
$2.83 per share

Miscellaneous

Free Float
40,931,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
1.70

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Jay S. Duker M.D. (Age 65)
    President, CEO & Director
    Comp: $848.5k
  • Mr. Michael Pine (Age 48)
    Chief Business Officer
    Comp: $764.85k
  • Mr. George O. Elston (Age 59)
    Executive VP & CFO
    Comp: $743.86k
  • Mr. Michael J. Maciocio
    Senior Vice President of Manufacturing & Operations
  • Mr. Said Saim Ph.D. (Age 66)
    Senior VP & CTO
  • Mr. Ron I. Honig Esq.
    Chief Legal Officer & Company Secretary
  • Ms. Jennifer Leonard
    Chief People Officer & Senior VP of IT
  • Dr. Dario A. Paggiarino (Age 67)
    Senior VP & Chief Medical Officer
    Comp: $694.19k
  • Mr. David Scott Jones (Age 57)
    Senior VP & Chief Commercial Officer
    Comp: $672.08k
  • Ms. Isabelle Lefebvre
    Chief Regulatory Officer














EYPT Stock Analysis - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings
or view top-rated stocks.

What is EyePoint Pharmaceuticals' stock price target for 2024?

7 brokerages have issued 12 month price objectives for EyePoint Pharmaceuticals' stock. Their EYPT share price targets range from $22.00 to $44.00. On average, they predict the company's share price to reach $33.86 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for EYPT
or view top-rated stocks among Wall Street analysts.

How have EYPT shares performed in 2024?

EyePoint Pharmaceuticals' stock was trading at $23.11 at the beginning of the year. Since then, EYPT shares have increased by 17.7% and is now trading at $27.21.
View the best growth stocks for 2024 here
.

Are investors shorting EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 4,750,000 shares, a decline of 7.6% from the January 31st total of 5,140,000 shares. Based on an average daily volume of 1,640,000 shares, the short-interest ratio is presently 2.9 days.
View EyePoint Pharmaceuticals' Short Interest
.

When is EyePoint Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our EYPT earnings forecast
.

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.11. The company earned $9.06 million during the quarter, compared to analyst estimates of $9.60 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 109.34% and a negative net margin of 235.51%. During the same period in the previous year, the firm earned ($0.30) EPS.

When did EyePoint Pharmaceuticals' stock split?

EyePoint Pharmaceuticals shares reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of EyePoint Pharmaceuticals own?
Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (9.86%), Price T Rowe Associates Inc. MD (5.36%), Price T Rowe Associates Inc. MD (5.36%), Vanguard Group Inc. (4.32%), Jennison Associates LLC (2.27%) and Perceptive Advisors LLC (0.00%). Insiders that own company stock include Cormorant Asset Management, Lp, Dario A Paggiarino, David Scott Jones, Ew Healthcare Partners, LP, Michael Craig Pine and Ye Liu.
View institutional ownership trends
.

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EYPT) was last updated on 3/1/2024 by MarketBeat.com Staff